CN112439054A - Teriparatide sustained-release gel injection and preparation method thereof - Google Patents
Teriparatide sustained-release gel injection and preparation method thereof Download PDFInfo
- Publication number
- CN112439054A CN112439054A CN201910804352.5A CN201910804352A CN112439054A CN 112439054 A CN112439054 A CN 112439054A CN 201910804352 A CN201910804352 A CN 201910804352A CN 112439054 A CN112439054 A CN 112439054A
- Authority
- CN
- China
- Prior art keywords
- teriparatide
- sustained
- poloxamer
- temperature
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010049264 Teriparatide Proteins 0.000 title claims abstract description 82
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 title claims abstract description 82
- 229960005460 teriparatide Drugs 0.000 title claims abstract description 82
- 238000002347 injection Methods 0.000 title claims abstract description 75
- 239000007924 injection Substances 0.000 title claims abstract description 75
- 238000013268 sustained release Methods 0.000 title claims abstract description 53
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 60
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 51
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000000463 material Substances 0.000 claims abstract description 33
- 229920001661 Chitosan Polymers 0.000 claims abstract description 14
- 229920001983 poloxamer Polymers 0.000 claims abstract description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 6
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 6
- 229960000502 poloxamer Drugs 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 230000007227 biological adhesion Effects 0.000 claims abstract description 5
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 4
- 239000001913 cellulose Substances 0.000 claims abstract description 4
- 229920002678 cellulose Polymers 0.000 claims abstract description 4
- 239000006174 pH buffer Substances 0.000 claims abstract description 4
- 239000004584 polyacrylic acid Substances 0.000 claims abstract description 4
- 239000000227 bioadhesive Substances 0.000 claims abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 87
- 238000003756 stirring Methods 0.000 claims description 79
- 239000008215 water for injection Substances 0.000 claims description 42
- 229960000583 acetic acid Drugs 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 34
- 238000001914 filtration Methods 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 27
- 229920001992 poloxamer 407 Polymers 0.000 claims description 26
- 229940044476 poloxamer 407 Drugs 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 229920001993 poloxamer 188 Polymers 0.000 claims description 19
- 229940044519 poloxamer 188 Drugs 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 15
- 239000012362 glacial acetic acid Substances 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000003139 buffering effect Effects 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000007974 sodium acetate buffer Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims 2
- 229940071643 prefilled syringe Drugs 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000003186 pharmaceutical solution Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 239000000022 bacteriostatic agent Substances 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 51
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 15
- 239000001632 sodium acetate Substances 0.000 description 15
- 235000017281 sodium acetate Nutrition 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 12
- 239000011521 glass Substances 0.000 description 11
- 208000001132 Osteoporosis Diseases 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 6
- 238000001879 gelation Methods 0.000 description 5
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003364 biologic glue Substances 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a teriparatide sustained-release gel injection and a preparation method thereof, and particularly discloses a teriparatide sustained-release gel injection which is prepared from the following components: teriparatide, a pH buffer component, a biological adhesion material, a temperature sensitive gel material, a pH regulator and a solvent; preferably, the temperature-sensitive gel material is selected from a combination of temperature-sensitive poloxamer and glycerol, and the bioadhesive material is selected from chitosan, hyaluronic acid, cellulose derivatives, polyacrylic acid or a combination thereof; the solvent is water. The teriparatide sustained-release gel injection disclosed by the invention is sustained-released for several days, so that the administration times can be obviously reduced, the compliance of a patient is improved, the treatment effect is improved, meanwhile, the use of a bacteriostatic agent is avoided, and the same effect is achieved.
Description
Technical Field
The invention relates to a preparation process of teriparatide sustained-release gel injection, belonging to the field of pharmaceutical preparations.
Background
Osteoporosis is a metabolic bone disease in which the balance between bone absorption and bone formation is disrupted after the physical function of the human body is reduced, resulting in increased bone fragility. Osteoporosis is classified into postmenopausal osteoporosis in women and senile osteoporosis. China is the country with the most population in the world, and people have also stepped into the elderly society, so that the development of medicines for preventing and treating osteoporosis has wide market demand and social significance.
Parathyroid hormone (PTH) regulates calcium and phosphorus metabolism in bone, increases serum calcium levels, decreases calcium clearance from the kidneys, and promotes bone absorption and release of calcium, thereby promoting new bone formation. Teriparatide is a chemically synthesized parathyroid hormone, can promote the formation of new bones, increase the mineral density of bones, and improve the bone density and microstructure of patients with osteoporosis, thereby reducing the risk of fracture, and is suitable for various types of osteoporosis.
The FDA approved teriparatide injection developed by American Gift corporation in 2002
Becomes the first drug approved by the FDA for treating osteoporosis. In 3 months 2011, teriparatide injection is approved by SFDA to enter the china market for the treatment of osteoporosis in postmenopausal women.
Currently, teriparatide injection developed by American Gift company
The prescription is as follows: glacial acetic acid, sodium acetate (anhydrous), mannitol, m-cresol, hydrochloric acid, sodium hydroxide and water for injection. M-cresol is a bacteriostatic agent and is easy to oxidize, so that unknown impurities are easy to generate in the preparation process of the existing teriparatide injection, and the stability of the injection is poor. The specification is 20 mug: 80 μ l, 2.4 mL/arm, with a recommended dose of 20 μ g per day by subcutaneous injection, the injection site being selected in the thigh or abdomen. The maximum time for total treatment was 24 months. The patient may receive only 1 treatment for a 24-month period for life. Futaiao is a prefilled pen type injector, and each pen is only used by one patient. The injection is administered with a new oneThe fungus injection needle is used for storing Futaiao in a refrigerator after each injection.
In the original preparation, the gel is a common injection, a patient needs to be injected subcutaneously every day, but the treatment period of osteoporosis is long, and long-time injection administration brings great pain and inconvenience to the patient, so that the compliance of the patient is poor, therefore, the development of the teriparatide preparation with long effect and slow release effect has important practical significance, the slow release of the gel injection is as long as several days, the administration times can be obviously reduced, the compliance of the patient can be improved, and the treatment effect can be improved.
The temperature sensitive slow release gel has a gelation mechanism of in-situ gel formed by the change of environmental temperature, contains temperature sensitive high molecular material, and forms non-chemical cross-linked gel due to the change of in vivo and in vitro temperature after administration. The injection is in a liquid state in vitro, has low viscosity, can be injected for administration, and after entering a joint cavity, the liquid medicine quickly forms uniform semisolid gel due to the rise of temperature, so that the retention time of the medicine in the joint cavity is prolonged, the full absorption of the medicine is facilitated, and the bioavailability of the teriparatide is improved.
Poloxamers are the most studied and used class of gel materials, and there are patents published: an amphiphilic polysaccharide derivative/poloxamer temperature-sensitive in-situ hydrogel and a preparation method thereof (patent number: CN 104888224B), the prepared in-situ hydrogel has higher stability and longer drug slow-release time, provides possibility for realizing injection administration and improving the bioavailability of drugs, and can be applied to a mucosal administration system, a transdermal administration system and an injection administration system.
Disclosure of Invention
The invention aims to overcome the defects of the dosage form in the prior art and provides a teriparatide sustained-release gel injection and a preparation method thereof, which are convenient to use, form a drug reservoir in muscle or joint cavity, have long drug action time and obviously reduce the drug administration times.
In order to achieve the above objects, one aspect of the present invention provides a teriparatide sustained-release gel injection, which is prepared from the following components: teriparatide, a pH buffer component, a biological adhesion material, a temperature sensitive gel material, a pH regulator and a solvent;
preferably, the temperature-sensitive gel material is selected from a combination of temperature-sensitive poloxamer and glycerol, and the bioadhesive material is selected from chitosan, hyaluronic acid, cellulose derivatives, polyacrylic acid or a combination thereof; the solvent is water.
In the technical scheme of the invention, the biological adhesive material refers to natural or synthetic high molecular substances with the capacity of adhering to the surface of cavity mucus or epithelial cells.
In the technical scheme of the invention, each 100ml of the teriparatide sustained-release gel injection is prepared from the following components:
in the technical scheme of the invention, the pH buffering component is selected from a buffering pair with a pH value of 3.5-5.5 after a buffering pair and a pH value regulator are added, preferably a glacial acetic acid and sodium acetate buffering pair, sodium dihydrogen phosphate and disodium hydrogen phosphate, citric acid and sodium citrate, and succinic acid.
In the technical scheme of the invention, the temperature-sensitive poloxamer is selected from poloxamer 407, poloxamer 188, a mixture of poloxamer 407 and poloxamer 188, preferably a mixture of poloxamer 407 and poloxamer 188 or more than 15g of poloxamer 407 in each 100ml of teriparatide slow-release gel injection; more preferably, the mass ratio of the poloxamer 407 to the poloxamer 188 is 1-6:1 or more than 16g of poloxamer 407 is contained in each 100ml of teriparatide sustained-release gel injection.
In the technical scheme of the invention, the addition amount of the glycerol is 50mg/ml-100mg/ml of the final concentration of the glycerol in the gel injection.
In the technical scheme of the invention, the biological adhesive material is selected from chitosan, hyaluronic acid, cellulose derivatives, polyacrylic acid or a combination thereof, and chitosan is preferred.
In the technical scheme of the invention, the pH regulator is selected from phosphoric acid, acetic acid, citric acid, hydrochloric acid and sodium hydroxide, preferably acetic acid.
In the technical scheme of the invention, the pH value buffering range of the pH buffer solution is 3.5-5.0.
In the technical scheme of the invention, the pH value of the teriparatide sustained-release gel injection is 3.8-4.5.
The invention also provides a preparation method of the teriparatide sustained-release gel injection, which comprises the following steps:
1) dissolving a teriparatide bulk drug in water for injection to obtain a first solution;
2) dissolving the biological adhesion material by using a pH buffer solution to obtain a second solution;
3) adding the temperature-sensitive gel material into the second solution, stirring and dissolving, and controlling the stirring temperature to be 0-10 ℃ to obtain a third solution;
4) uniformly mixing the first solution and the third solution at 0-10 deg.C, adjusting pH to 3.5-5.5 with pH regulator, and diluting to desired volume with injectable water;
5) sterilizing and filtering with 0.22 μm filter under aseptic condition, and controlling the filtering temperature at 0-15 deg.C;
6) and (5) subpackaging the filtered and sterilized liquid medicine.
In the technical scheme of the invention, sterile liquid medicine is subpackaged in penicillin bottles, prefilled syringes or snap bottles, preferably prefilled syringes.
In the technical scheme of the invention, the concentration of acetic acid is different from that of glacial acetic acid, the concentration of acetic acid is 36%, and the concentration of glacial acetic acid is 98%.
Advantageous effects
1. The common teriparatide injection has no slow release effect, and patients need to inject the injection every day, so that great pain and inconvenience are brought to the patients; the teriparatide sustained-release gel injection disclosed by the invention has sustained release for several days, so that the administration times can be obviously reduced, the compliance of a patient is improved, and the treatment effect is improved.
2. The prescription process of the invention avoids using bacteriostatic agents and achieves the same effect.
Detailed Description
The embodiment of the invention discloses a preparation method of teriparatide sustained-release gel injection. Those skilled in the art can modify the process recipe implementation appropriately based on the contents provided herein. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the method of the present invention has been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the formulations and processes described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of the present invention without departing from the spirit and scope of the invention.
For a further understanding of the present invention, reference will now be made in detail to the following examples. The following examples will help understanding of the present invention, but the following examples are only for illustrating the implementation of the present invention more specifically and are not intended to limit the technical scheme of the present invention.
Comparative example 1 teriparatide sustained Release gel injection
1) Dissolving teriparatide 25mg in 10ml of water for injection;
2) dissolving 41mg of glacial acetic acid in 50ml of water for injection, adding 10mg of sodium acetate, stirring and dissolving, adding 4.54g of mannitol, stirring and dissolving;
3) adding 0.3g of m-cresol into the mixture obtained in the step 2), and stirring and dissolving to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid in the step 1) into the step 3), stirring uniformly, adjusting the pH value to 4.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterile filtration through a 0.22 μm filter.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C. Comparative example 2 teriparatide sustained Release gel injection
1) Dissolving teriparatide 25mg in 10ml of water for injection;
2) dissolving 41mg of glacial acetic acid in 50ml of water for injection, adding 10mg of sodium acetate, and stirring for dissolving;
3) adding 15g of poloxamer 407 into the mixture obtained in the step 2), stirring and dissolving the mixture in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 4.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C. Comparative example 3 teriparatide sustained Release gel injection
1) Dissolving teriparatide 25mg in 10ml of water for injection;
2) dissolving 41mg of glacial acetic acid in 50ml of water for injection, adding 500mg of chitosan, stirring and dissolving, and then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 5g of glycerol, 14g of poloxamer 407 and 0.5g of poloxamer 188 into the mixture obtained in step 2), stirring and dissolving in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 4.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C.
Example 1 sustained Release gel injection of teriparatide
1) Dissolving teriparatide 25mg in 10ml of water for injection;
2) dissolving 41mg of glacial acetic acid in 50ml of water for injection, adding 800mg of chitosan, stirring and dissolving, and then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 7.5g of glycerol, 18g of poloxamer 407 and 3g of poloxamer 188 into the mixture obtained in step 2), stirring and dissolving in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 4.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C.
Example 2 sustained Release gel injection of teriparatide
1) Dissolving teriparatide 25mg in 10ml of water for injection;
2) dissolving 41mg of glacial acetic acid in 50ml of water for injection, adding 200mg of hyaluronic acid, stirring and dissolving, and then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 5g of glycerol, 18g of poloxamer 407 and 3g of poloxamer 188 into the mixture obtained in step 2), stirring and dissolving in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 4.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) And (3) subpackaging the filtered and sterilized liquid medicine into 2mL penicillin bottles (1.15mL), and storing in a refrigerator at the temperature of 2-8 ℃ to obtain the drug. Example 3 sustained Release gel injection of teriparatide
1) Dissolving teriparatide 5mg in 10ml of water for injection;
2) dissolving 41mg of glacial acetic acid in 50ml of water for injection, adding 5000mg of chitosan, stirring and dissolving, and then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 10g of glycerol, 12g of poloxamer 407 and 3g of poloxamer 188 into the mixture obtained in step 2), stirring and dissolving in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 4.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 10-15 deg.C.
6) The filtrate is packaged into card bottle (3.3ml), and stored in refrigerator at 2-8 deg.C.
Example 4 sustained Release gel injection of teriparatide
1) Dissolving teriparatide 75mg in 10ml of water for injection;
2) dissolving 41mg of glacial acetic acid in 30ml of water for injection, adding 500mg of chitosan, stirring and dissolving, and then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 5g of glycerol, 29.17g of poloxamer 407 and 5.83g of poloxamer 188 into the mixture obtained in step 2), stirring and dissolving in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 4.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C.
Example 5 sustained Release gel injection of teriparatide
1) Dissolving teriparatide 15mg in 10ml of water for injection;
2) dissolving 41mg of glacial acetic acid in 50ml of water for injection, adding 500mg of chitosan, stirring and dissolving, and then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 7.5g of glycerol, 20g of poloxamer 407 and 5g of poloxamer 188 into the mixture obtained in step 2), stirring and dissolving in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 3.5 with acetic acid, and fixing the volume to 100ml with water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C.
Example 6 sustained Release gel injection of teriparatide
1) Dissolving teriparatide 15mg in 10ml of water for injection;
2) dissolving 41mg of glacial acetic acid in 50ml of water for injection, adding 1000mg of hyaluronic acid, stirring and dissolving, and then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 5g of glycerol, 20g of poloxamer 407 and 5g of poloxamer 188 into the mixture obtained in step 2), stirring and dissolving in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 5.5 with acetic acid, and fixing the volume to 100ml with water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C.
Example 7 sustained Release gel injection of teriparatide
1) Dissolving teriparatide 10mg in water for injection 10 ml;
2) dissolving 2.5g of sodium dihydrogen phosphate dihydrate in 50ml of water for injection, adding 800mg of chitosan, stirring and dissolving, and then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 7.5g of glycerol, 18g of poloxamer 407 and 3g of poloxamer 188 into the mixture obtained in step 2), stirring and dissolving in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 5.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C.
Example 8 sustained Release gel injection of teriparatide
1) Dissolving teriparatide 20mg in 10ml of water for injection;
2) dissolving 1.0g of citric acid monohydrate in 50ml of water for injection, adding 800mg of chitosan, stirring and dissolving, and then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 7.5g of glycerol, 20g of poloxamer 407 and 10g of poloxamer 188 into the mixture obtained in step 2), stirring and dissolving in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 4.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C.
Example 9 sustained Release gel injection of teriparatide
1) Dissolving teriparatide 25mg in 10ml of water for injection;
2) dissolving 1.0g of citric acid monohydrate in 50ml of water for injection, adding 2000mg of chitosan, stirring and dissolving, then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 7.5g of glycerol, 10g of poloxamer 407 and 10g of poloxamer 188 into the mixture obtained in step 2), stirring and dissolving in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 4.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C.
Example 10 sustained Release gel injection of teriparatide
1) Dissolving teriparatide 25mg in 10ml of water for injection;
2) dissolving 41mg of glacial acetic acid in 50ml of water for injection, adding 800mg of chitosan, stirring and dissolving, and then adding 10mg of sodium acetate, stirring and dissolving;
3) adding 7.5g of glycerol and 20g of poloxamer 407 into the mixture obtained in the step 2), stirring and dissolving the mixture in ice bath, and controlling the stirring temperature to be 0-10 ℃ to obtain an auxiliary material solution;
4) adding the Chinese medicinal liquid of 1) into the liquid of 3), stirring uniformly, controlling the stirring temperature at 0-10 ℃, adjusting the pH value to 4.0 by using acetic acid, and fixing the volume to 100ml by using water for injection;
5) sterilizing and filtering with 0.22 μm filter, and controlling the filtering temperature at 0-10 deg.C.
6) The filtrate is filled into pre-filled glass syringe (1.05ml) and stored in refrigerator at 2-8 deg.C.
Example 11 phase transition temperature and reversibility measurement of teriparatide sustained-Release gel injection
Test samples: teriparatide sustained-release gel injection or teriparatide injection prepared according to the formulation and preparation method described in examples 1-10 and comparative example 1.
The phase transition temperature measuring method comprises the following steps: placing 1mL teriparatide sustained-release gel injection in a 10mL test tube, gradually heating in a constant temperature water bath kettle to 0.1 deg.C for 1min, stabilizing after reaching a given temperature, judging according to flow-no-flow principle, and recording temperature. And after the phase change occurs, taking out the liquid crystal, putting the liquid crystal in a refrigerator, observing whether the liquid crystal is recovered after 10min, and judging whether the phase change is reversible.
The test results are shown in the following table:
TABLE 1 results of liquid phase transition temperature and reversibility of teriparatide sustained-release gel injection
The average temperature of human body is 36-37 deg.C, so that the sample can be changed into semisolid gel at body temperature as long as it is liquid at normal temperature, i.e. the sample with gelation temperature of 20-37 deg.C is satisfactory, and is more excellent for sample with temperature of 25-33 deg.C.
Test results show that the teriparatide sustained-release gel injection is liquid at the gelation temperature of 20-37 ℃, is convenient to administer and good in patient compliance, can form semisolid gel at the gelation temperature of 1-3 min after being injected into muscles or joint cavities, has high gelation speed, forms a drug storage, slowly releases active substance teriparatide and exerts curative effect. And when the mass ratio of the poloxamer 407 to the poloxamer 188 is 1-6:1 or more than 16g of poloxamer 407 is contained in each 100ml of teriparatide sustained-release gel injection, the effect is better.
EXAMPLE 12 examination of in vitro Release degree of teriparatide sustained-Release gel injection
The in vitro release behavior of the teriparatide sustained-release gel injection is examined by adopting a constant temperature shaking table method: taking 2g of teriparatide sustained-release gel injection or teriparatide injection into a penicillin bottle (phi 13mm), placing the teriparatide sustained-release gel injection or the teriparatide injection into a constant-temperature shaking table at 37 ℃ for 10min, then adding 2mL of acetic acid-sodium acetate buffer solution (pH4.0) and vibrating at 37 ℃ at 50rpm, respectively sampling 0.5mL in 4h, 8h, 12h, 24h, 48h, 72h, 120h, 168h and 240h, supplementing 0.5mL of acetic acid-sodium acetate buffer solution (pH4.0), treating 0.5mL of a sample taken out each time, taking 20 mu L of the sample to inject into a high-performance liquid chromatograph, obtaining the concentration of the sample solution, calculating the cumulative release degree Q, and drawing a curve result shown as the following formula:
c in formula 1-1nThe drug concentration (mg/mL), C, was determined for the nth time sampling pointiThe drug concentration (mg/mL) was determined for the ith time sampling point, and M was the total amount of drug in 2g of teriparatide sustained release gel injection.
TABLE 2 cumulative release results for teriparatide sustained release gel injections
Note 1 because it did not gel at 37 deg.C, this set of experiments was done with constant temperature shaking (50rpm) at 39 deg.C
The teriparatide sustained-release gel injection in the embodiment 1-10 has an obvious sustained-release effect, avoids the peak-valley phenomenon of the drug concentration, has long drug action time, reduces the administration times, and greatly improves the compliance of patients.
Claims (10)
1. A teriparatide sustained-release gel injection is prepared from the following components: teriparatide, a pH buffer component, a biological adhesion material, a temperature sensitive gel material, a pH regulator and a solvent;
preferably, the temperature-sensitive gel material is selected from a combination of temperature-sensitive poloxamer and glycerol, and the bioadhesive material is selected from chitosan, hyaluronic acid, cellulose derivatives, polyacrylic acid or a combination thereof; the solvent is water.
2. The teriparatide sustained-release gel injection according to claim 1, wherein each 100ml of the injection is prepared from the following components:
3. the teriparatide sustained release gel injection according to any one of claims 1 to 2, wherein the pH buffering component is selected from the group consisting of a buffer pair having a pH of between 3.5 and 5.5 after addition of a buffer pair and a pH adjusting agent, preferably a glacial acetic acid and sodium acetate buffer pair, sodium dihydrogen phosphate and disodium hydrogen phosphate, citric acid and sodium citrate, succinic acid.
4. The teriparatide sustained-release gel injection according to any one of claims 1 to 3, wherein the temperature-sensitive poloxamer is selected from poloxamer 407, poloxamer 188, a mixture of poloxamer 407 and poloxamer 188, preferably a mixture of poloxamer 407 and poloxamer 188 or more than 15g of poloxamer 407 in each 100ml of teriparatide sustained-release gel injection; more preferably, the mass ratio of the poloxamer 407 to the poloxamer 188 is 1-6:1 or more than 16g of poloxamer 407 is contained in each 100ml of teriparatide sustained-release gel injection.
5. The sustained-release gel injection of teriparatide according to any one of claims 1 to 4, wherein glycerol is added in an amount such that the final concentration thereof in the gel injection is 50mg/ml to 100 mg/ml.
6. The teriparatide sustained-release gel injection according to any one of claims 1 to 5, wherein the pH regulator is selected from phosphoric acid, acetic acid, citric acid, hydrochloric acid and sodium hydroxide, preferably acetic acid.
7. The teriparatide sustained release gel injection according to any one of claims 1 to 6, wherein the pH buffer has a pH value buffering range of 3.5 to 5.0.
8. The teriparatide sustained-release gel injection according to any one of claims 1 to 7, which has a pH value of 3.8 to 4.5.
9. The method for preparing teriparatide sustained release gel injection according to any one of claims 1 to 8, which comprises the following steps:
1) dissolving a teriparatide bulk drug in water for injection to obtain a first solution;
2) dissolving the biological adhesion material by using a pH buffer solution to obtain a second solution;
3) adding the temperature-sensitive gel material into the second solution, stirring and dissolving, and controlling the stirring temperature to be 0-10 ℃ to obtain a third solution;
4) uniformly mixing the first solution and the third solution at 0-10 deg.C, adjusting pH to 3.5-5.5 with pH regulator, and diluting to desired volume with injectable water;
5) sterilizing and filtering with 0.22 μm filter under aseptic condition, and controlling the filtering temperature at 0-15 deg.C;
6) and (5) subpackaging the filtered and sterilized liquid medicine.
10. The method of claim 9, wherein the sterile pharmaceutical solution is dispensed into a vial, pre-filled syringe or cartridge, preferably a pre-filled syringe.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910804352.5A CN112439054B (en) | 2019-08-28 | 2019-08-28 | Teriparatide sustained-release gel injection and preparation method thereof |
| PCT/CN2019/121291 WO2021036058A1 (en) | 2019-08-28 | 2019-11-27 | Teriparatide sustained release gel injection solution and preparation method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910804352.5A CN112439054B (en) | 2019-08-28 | 2019-08-28 | Teriparatide sustained-release gel injection and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112439054A true CN112439054A (en) | 2021-03-05 |
| CN112439054B CN112439054B (en) | 2023-05-16 |
Family
ID=74683779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910804352.5A Active CN112439054B (en) | 2019-08-28 | 2019-08-28 | Teriparatide sustained-release gel injection and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112439054B (en) |
| WO (1) | WO2021036058A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114948795B (en) * | 2022-07-08 | 2023-09-08 | 上海信悉智能技术有限公司 | Temperature-sensitive gel mask liquid and preparation method thereof |
| CN115120555B (en) * | 2022-07-27 | 2024-04-26 | 塔里木大学 | Minocycline hydrochloride temperature-sensitive hydrogel for local sustained release delivery and preparation method thereof |
| CN115634234B (en) * | 2022-10-24 | 2024-03-22 | 山西医科大学 | Poloxamer 407 antibacterial anti-inflammatory temperature-sensitive hydrogel containing chlorhexidine/gardenin/hyaluronic acid and preparation and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156834A (en) * | 2007-10-30 | 2008-04-09 | 深圳南粤药业有限公司 | Ammonia temperature responsive form gel and its preparation method |
| CN101189025A (en) * | 2005-06-03 | 2008-05-28 | 财团法人牧岩生命工学研究所 | Stabilized parathyroid hormone composition comprising parathyroid hormone, buffer and stabilizing agent |
| CN103157096A (en) * | 2013-03-27 | 2013-06-19 | 深圳翰宇药业股份有限公司 | Teriparatide sustained-release microsphere and preparation method thereof |
| CN103239389A (en) * | 2013-06-03 | 2013-08-14 | 南京泽恒医药技术开发有限公司 | Preparation method of progestin sustained-release gel for treating threatened abortion |
| CN103301058A (en) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | Composition for teriparatide injection, and preparation method and preparation thereof |
| CN104622794A (en) * | 2015-01-16 | 2015-05-20 | 北京大学 | Gel injection combining molecular targeted drug and cytotoxic drug |
| CN104888224A (en) * | 2015-03-25 | 2015-09-09 | 中山大学 | Amphipathic polysaccharide derivative/poloxamer thermo-sensitive type in-situ hydrogel and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY120063A (en) * | 1997-12-09 | 2005-08-30 | Lilly Co Eli | Stabilized teriparatide solutions |
| EP2052736A1 (en) * | 2007-10-26 | 2009-04-29 | Nycomed Danmark ApS | Parathyroid hormone formulations und uses thereof |
| CN101297973B (en) * | 2008-05-22 | 2010-06-09 | 武汉华纳生物工程有限公司 | Highly bioadhesive and thermosensitive hydrogel, and preparation method and application thereof |
| US8883862B2 (en) * | 2012-01-12 | 2014-11-11 | Kaohsiung Medical University | Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel |
| CN109966557A (en) * | 2018-12-05 | 2019-07-05 | 博志生物科技有限公司 | The preparation method and application of the GelMA hydrogel of local sustained release Abaloparatide or related polypeptide |
-
2019
- 2019-08-28 CN CN201910804352.5A patent/CN112439054B/en active Active
- 2019-11-27 WO PCT/CN2019/121291 patent/WO2021036058A1/en active Application Filing
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101189025A (en) * | 2005-06-03 | 2008-05-28 | 财团法人牧岩生命工学研究所 | Stabilized parathyroid hormone composition comprising parathyroid hormone, buffer and stabilizing agent |
| CN101156834A (en) * | 2007-10-30 | 2008-04-09 | 深圳南粤药业有限公司 | Ammonia temperature responsive form gel and its preparation method |
| CN103157096A (en) * | 2013-03-27 | 2013-06-19 | 深圳翰宇药业股份有限公司 | Teriparatide sustained-release microsphere and preparation method thereof |
| CN103239389A (en) * | 2013-06-03 | 2013-08-14 | 南京泽恒医药技术开发有限公司 | Preparation method of progestin sustained-release gel for treating threatened abortion |
| CN103301058A (en) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | Composition for teriparatide injection, and preparation method and preparation thereof |
| CN104622794A (en) * | 2015-01-16 | 2015-05-20 | 北京大学 | Gel injection combining molecular targeted drug and cytotoxic drug |
| CN104888224A (en) * | 2015-03-25 | 2015-09-09 | 中山大学 | Amphipathic polysaccharide derivative/poloxamer thermo-sensitive type in-situ hydrogel and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021036058A1 (en) | 2021-03-04 |
| CN112439054B (en) | 2023-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU734781B2 (en) | Stable insulin formulations | |
| CN1273187C (en) | Insulin preparations, which donot contain any zinc or only small quantity of zinc of improved stability | |
| CN112439054A (en) | Teriparatide sustained-release gel injection and preparation method thereof | |
| WO2013177565A1 (en) | Insulin-pramlintide compositions and methods for making and using them | |
| KR100486146B1 (en) | Improved process and composition for therapeutic cisplatin | |
| CN110678194B (en) | Octreotide injection | |
| JP2005538068A (en) | Solution containing high concentration of human growth hormone (hGH) and phenol | |
| JPH01287041A (en) | Sustained release preparation | |
| RU2519654C2 (en) | Tetrodotoxin-based lyophilised preparation and method of its production | |
| EP1283051A1 (en) | Stable insulin formulations | |
| CN110755380B (en) | Parathyroid hormone 1-34 nasal spray, preparation method and application thereof | |
| US11672863B2 (en) | Enhanced solubility drug-containing formulations | |
| JP2021511386A (en) | Treatment of obesity with low-dose stable glucagon Treatment of hypoglycemia after surgery | |
| CN104800172A (en) | Carbazochrome sodium sulfonate powder injection for injection and preparation method thereof | |
| Stickelmeyer et al. | Stability of U-10 and U-50 dilutions of insulin lispro | |
| JP3103535B2 (en) | Prefilled syringe preparation of calcitonin | |
| CN111603439A (en) | Long-acting in-situ phase change gel injection of brexpiprazole and preparation method thereof | |
| JP2021506933A (en) | Treatment of Exercise-Induced Hypoglycemia in Type 1 Diabetes and Insulin Use Type 2 Diabetes | |
| CN114096269B (en) | High concentration insulin formulations | |
| CN112451475B (en) | Long-acting sustained-release gel for treating cavernous pulmonary tuberculosis | |
| RU2777554C2 (en) | Octreotide injection | |
| CN116270980A (en) | Pharmaceutical composition containing GLP-1 analogue and preparation method thereof | |
| CN115300639A (en) | Sustained-release pharmaceutical composition containing deglutated insulin and preparation method thereof | |
| CN111214643A (en) | Octreotide composition based on subcutaneous gel sustained release, preparation method and application | |
| JP2024501166A (en) | Sustained release pharmaceutical composition of fulvestrant and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |